BioSpace News Archive

Acquisition aims to maximize synergy through combined technologies

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to evaluate PTI-125 in patients with Alzheimer’s disease. The Company’s lead investigational drug, PTI-125, seeks to improve both neurodegeneration and neuroinflammation in patients with Alzheimer’s disease. “We believe the ability of our drug to improve multiple function

NTT Research PHI Lab Director to Support Coherent Ising Machines (CIMs) Initiative

Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. Th

DarioHealth® Receives Endorsement from the Organization for the Review of Care & Health Applications (ORCHA)

A study published in the respected Nature Communications journal highlights the promise of technology being developed by Turn Biotechnologies to treat age-related health conditions.

Debiopharm, a Swiss-based biopharmaceutical company, announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anh

Telehealth technologies are available everywhere for any healthcare provider willing to commit to implementing a system.

Data is beginning to emerge on how the new Coronavirus and the infection it causes, N-CoV19, affects pregnancy, delivery, fertility and fertility treatments.

Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced the appointment of David Sable, M.D., to its Board of Directors. A world-renowned reproductive endocrinologist, Dr. Sable brings more than 30 years of reproductive health and medical expertise to Ohana. Dr. Sable currently directs healthcare and life sciences inve